Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285286 | 0.94 | TSHR (0.58) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL141029 | 0.87 | TSHR (0.52) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL133590 | 0.85 | TSHR (0.53) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL332090 | 0.83 | TSHR (0.59) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL853573 | 0.83 | ATM (0.41) | TSHRALDH1A1CYP3A4HPGDATM | |
| SCHEMBL28009740 | 0.82 | TSHR (0.50) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL16301383 | 0.82 | TSHR (0.43) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL374776 | 0.81 | TSHR (0.57) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL81411 | 0.81 | TSHR (0.57) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL7508187 | 0.81 | TSHR (0.57) | TSHRALDH1A1CYP3A4HPGDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725470-A1 | CURABLE DENTAL COMPOSITION | Kuraray Noritake Dental Inc. (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20250032366-A1 | DENTAL CURABLE COMPOSITION | KURARAY NORITAKE DENTAL INC. (JP) | 2025-01-30 | — | — | US | disclosed |
| US-20250009607-A1 | DENTAL COMPOSITION AND METHOD OF PRODUCTION THEREOF, AND SURFACE-TREATED FILLER FOR DENTAL USE | KURARAY NORITAKE DENTAL INC. (JP) | 2025-01-09 | — | — | US | disclosed |
| WO-2024253204-A1 | CURABLE DENTAL COMPOSITION | クラレノリタケデンタル株式会社 | 2024-12-12 | — | — | WO | disclosed |
| EP-4464301-A1 | DENTAL COMPOSITION, METHOD FOR MANUFACTURING SAME, AND DENTAL SURFACE-TREATED FILLER | Kuraray Noritake Dental Inc. (JP) | 2024-11-20 | — | — | EP | disclosed |
| EP-4445891-A1 | DENTAL CURABLE COMPOSITION | Kuraray Noritake Dental Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| CN-118338879-A | Curable composition for dental use | 可乐丽则武齿科株式会社 | 2024-07-12 | — | — | CN | disclosed |
| US-11787891-B2 | Modified block copolymer composition | ZEON CORPORATION (JP) | 2023-10-17 | — | — | US | disclosed |
| WO-2023136337-A1 | DENTAL COMPOSITION, METHOD FOR MANUFACTURING SAME, AND DENTAL SURFACE-TREATED FILLER | クラレノリタケデンタル株式会社 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023106419-A1 | DENTAL CURABLE COMPOSITION | クラレノリタケデンタル株式会社 | 2023-06-15 | — | — | WO | disclosed |
| US-6841694-B2 | Process for stabilizing unsaturated organosilicon compounds | WACKER-CHEMIE GMBH (DE) | 2005-01-11 | — | — | US | disclosed |
| US-6815554-B2 | REACTING A HALOALKYLSILANE WITH A SALT OF AN UNSATURATED CARBOXYLIC ACID IN THE PRESENCE OF A PHASE TRANSFER CATALYST; BONDING AGENTS | WACKER-CHEMIE GMBH (DE) | 2004-11-09 | — | — | US | disclosed |
| EP-1469002-A1 | Method for stabilizing unsaturated organo-silicon compounds | Wacker-Chemie GmbH (DE) | 2004-10-20 | — | — | EP | disclosed |
| US-20040171859-A1 | Process for stabilizing unsaturated organosilicon compounds | WACKER-CHEMIE GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| US-6566549-B1 | Forming oligomers of vinyl acetate and oligomers of vinyl alcohol; fully saturated and terminally unsaturated oligomers | ROHM AND HAAS COMPANY | 2003-05-20 | — | — | US | disclosed |
| US-20020151736-A1 | PROCESS FOR PREPARING UNSATURATED ORGANOSILICON COMPOUNDS | WACKER-CHEMIE GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| EP-1249454-A1 | Preparation of unsaturated organo-silicon compounds | Wacker-Chemie GmbH (DE) | 2002-10-16 | — | — | EP | disclosed |
| US-20020111448-A1 | Continuous polymerization process and products therefrom | GREENBLATT GARY DAVID (US) | 2002-08-15 | — | — | US | disclosed |
| US-20020082371-A1 | Continuous polymerization process and products therefrom | GREENBLATT GARY DAVID (US) | 2002-06-27 | — | — | US | disclosed |
| EP-1010706-A2 | Continuous polymerization process and products therefrom | ROHM AND HAAS COMPANY (US) | 2000-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171859-A1 | Process for stabilizing unsaturated organosilicon compounds | ELOVL1, ELOVL6, DEGS1 | TSHR 4650/4885ALDH1A1 402/4885CYP3A4 3126/4885 |
| US-20250032366-A1 | DENTAL CURABLE COMPOSITION | H1-0, COL1A1, CHAF1B | TSHR 4352/4885ALDH1A1 1530/4885CYP3A4 3913/4885 |
| US-20250009607-A1 | DENTAL COMPOSITION AND METHOD OF PRODUCTION THEREOF, AND SURFACE-TREATED FILLER FOR DENTAL USE | CAD, SEM1, CAPZA1 | TSHR 3083/4885ALDH1A1 382/4885CYP3A4 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.